U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2015
472
Substance Class Protein
Created
by admin
on Mon Mar 31 21:04:22 GMT 2025
Edited
by admin
on Mon Mar 31 21:04:22 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
DLG4EML025
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SECUKINUMAB
DASH   INN   USAN   WHO-DD  
USAN   INN  
Official Name English
SECUKINUMAB (GENETICAL RECOMBINATION)
Preferred Name English
AIN457
Code English
AIN-457
Code English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL17A (INTERLEUKIN 17A, IL-17A)), HOMO SAPIENS MONOCLONAL ANTIBODY
Common Name English
COSENTYX
Brand Name English
SECUKINUMAB [USAN]
Common Name English
Secukinumab [WHO-DD]
Common Name English
AIN457A
Code English
SECUKINUMAB [JAN]
Common Name English
SECUKINUMAB [PURPLE BOOK CDER]
Common Name English
secukinumab [INN]
Common Name English
SECUKINUMAB [MI]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS COSENTYX (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
WHO-ATC L04AC10
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
WHO-VATC QL04AC10
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
NDF-RT N0000191495
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
NCI_THESAURUS C574
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
FDA ORPHAN DRUG 281309
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
Code System Code Type Description
CAS
1229022-83-6
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
DAILYMED
DLG4EML025
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
NCI_THESAURUS
C152315
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL1743068
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
SMS_ID
100000126309
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
JAPANESE REVIEW
COSENTYX (INITIAL APPROVAL)
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY APPROVED DECEMBER 2014
MERCK INDEX
m11827
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
USAN
XX-120
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
CAS
875356-43-7
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
ALTERNATIVE
EVMPD
SUB33242
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
WIKIPEDIA
Secukinumab
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
DRUG CENTRAL
4934
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
LACTMED
Secukinumab
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
RXCUI
1599788
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY RxNorm
NDF-RT
N0000191494
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY Interleukin-17A Antagonists [MoA]
INN
9182
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
JAPANESE REVIEW
COSENTYX (PARTIAL CHANGE APPROVAL)
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY APPROVED DECEMBER 2015
IUPHAR
8078
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
DRUG BANK
DB09029
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
FDA UNII
DLG4EML025
Created by admin on Mon Mar 31 21:04:22 GMT 2025 , Edited by admin on Mon Mar 31 21:04:22 GMT 2025
PRIMARY
From To
1_22 1_96
1_154 1_210
1_271 1_331
1_377 1_435
2_22 2_96
2_154 2_210
2_271 2_331
2_377 2_435
3_23 3_89
3_135 3_195
4_23 4_89
4_135 4_195
1_230 3_215
2_230 4_215
1_236 2_236
1_239 2_239
Glycosylation Link Type Site
N 1_307
N 2_307
Related Record Type Details
INTERLEUKIN-17A
TARGET -> INHIBITOR
Related Record Type Details
SECUKINUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966